



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

#16  
JB  
3/12/13  
(NE)

Application of: **Yu, et al.**

Application Number: 09/589,285

Group Art Unit: 1646

Filed: June 8, 2000

Examiner: Bunner, Bridget

Title: **Methods of Treatment of Immune System Related Disorders Using Neutrokinin-alpha (as amended)**

Atty. Docket No. PF343P3C4

TECH CENTER 1600/2900

MAR 10 2003

RECEIVED

**AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.116**

**BOX AF**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Official Action dated September 6, 2002 (Paper No. 13), Applicants request that the following amendments and remarks be entered into the above-identified application. Applicants submit concurrently herewith:

- (a) Version with Markings to Show Changes Made;
- (b) Exhibit A: Huard et al., "T cell costimulation by the TNF Ligand BAFF." *The Journal of Immunology*, (2001) 167:6225-6331;
- (c) Exhibit B: Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2." *Immunity* (2002) 10:515-24;
- (d) Exhibit C: partially redacted excerpt from Human Genome Sciences' Investigational New Drug Application for the use of BLyS in the treatment of combined variable immunodeficiency;
- (e) A Notice of Appeal;
- (f) Petition For Extension of Time Under 37 C.F.R. § 1.136(a); and
- (g) Fee Transmittal Sheet.

OK to enter  
BSG  
10/10/03